文献速递毛发、甲与色素性疾病

局部JAK抑制剂Delgocitinib乳膏治疗额部纤维性脱发的随机对照试验

Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia.
PubMed 文献 · J Invest Dermatol · 2025-10-14

这项2a期随机双盲探索性试验将30例成人女性额部纤维性脱发患者随机分配至2% Delgocitinib乳膏组或乳膏基质组,治疗12周。Delgocitinib组病灶中Th1相关生物标志物CXCL9表达显著下调(-3.10;P < .05),转录组谱平均改善4%(P < .001),而基质组病灶恶化33%。Delgocitinib乳膏耐受性良好,探索性临床严重程度终点有改善。

要点

  • Delgocitinib乳膏治疗12周使FFA病灶CXCL9表达显著下调(-3.10;P < .05)。
  • Delgocitinib组转录组谱平均改善4%,基质组恶化33%。
  • Delgocitinib乳膏耐受性良好,探索性临床终点有改善。

核心结论

  • Delgocitinib乳膏改善了FFA病灶的转录组谱,可能有望作为FFA的局部治疗选择。

研究设计与样本

  • 2a期随机双盲探索性试验,纳入30例成人女性FFA患者,随机分配至20 mg/g(2%)Delgocitinib乳膏组(n=15)或乳膏基质组(n=15),治疗12周。

主要发现

  • Delgocitinib组病灶CXCL9表达显著下调(-3.10;P < .05),CXCL10(-2.60;P < .1)和IFN-γ(-1.49;P = .22)下降不显著。
  • Delgocitinib组病灶转录组谱平均改善4%(P < .001),基质组病灶恶化33%。
  • Delgocitinib乳膏耐受性良好,探索性临床严重程度终点有改善。

临床怎么用

  • Delgocitinib乳膏可能作为FFA的潜在局部治疗选择,但需进一步研究确认疗效。

局限性

  • 样本量小,生物标志物分析仅至第12周,疗效终点为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia with generally poor prognosis if untreated and no approved treatment options. OBJECTIVE: The aim of this study was to evaluate changes in the molecular signature of FFA lesions after application of delgocitinib cream. Safety, tolerability, and efficacy were also investigated. METHODS: This was a phase 2a, randomized, double-blind, exploratory trial of 20 mg/g delgocitinib cream (2%) versus cream vehicle in patients with FFA. RESULTS: A total of 30 adult females with FFA were randomized to delgocitinib cream (n = 15) or cream vehicle (n = 15). After 12 weeks, expression of the T helper 1-related biomarker CXCL9 was significantly downregulated (-3.10; P < .05), whereas there were nonsignificant reductions in CXCL10 (-2.60; P < .1) and IFN-γ (-1.49; P = .22) in lesions treated with delgocitinib cream but not cream vehicle. Delgocitinib-treated lesions had a small but significant mean improvement in transcriptomic profile (4%; P < .001), whereas lesions treated with cream vehicle worsened (33%). Delgocitinib cream was well-tolerated and associated with improvements in exploratory clinical severity endpoints. LIMITATIONS: Limitations of the trial include small sample size, biomarker analyses only being conducted to week 12, and the exploratory nature of efficacy endpoints. CONCLUSION: Delgocitinib cream resulted in an improvement in the transcriptomic profile of lesions and may have potential as a topical treatment for FFA. This study is registered with NCT05332366.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Martin A, Shokrian N, Kelley KJ, et al. Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. J Invest Dermatol. 2025. PMID: 41101628. doi:10.1016/j.jid.2025.09.375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。